Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct-Dec;114(4):1114-7.

[Tamoxifen and endometrial pathology]

[Article in Romanian]
Affiliations
  • PMID: 21500468

[Tamoxifen and endometrial pathology]

[Article in Romanian]
M Negoiţă et al. Rev Med Chir Soc Med Nat Iasi. 2010 Oct-Dec.

Abstract

Tamoxifen is a non-steroid antiestrogen, used as adjuvant therapy for breast carcinoma in women with positive estrogen receptor (ER+). In this report we evaluated endometrial histological changes in women treated with Tamoxifen for ER+ breast carcinoma.

Material and method: We performed transvaginal ultrasonography for the endometrial thickness and biopsy of endometrium on a group of 125 symptomatic women with Tamoxifen therapy for ER+ breast carcinoma. The endometrial specimens were histologically processed for histological diagnosis.

Results: Of all patients, 49.6% had endometrial pathology (women with functional hemorrhage), and 32% had atrophic endometrium. Endometrial pathology was represented by endometrial simple hyperplasia 17.6%, and endometrial complex hyperplasia 8.8%. Endometrial complex hyperplasia with atypia was found in 5.6%, endometrial polyps in 11.2%, endometrial carcinoma in 4.8% and müllerian mixt tumor in 1.6%.

Conclusions: Endometrial pathology was more likely to be diagnosed in gynecological symptomatic postmenopausal and premenopausal women with breast carcinoma treated with Tamoxifen. Therefore, it is necessary that these patients to be supervise, first, with transvaginal ultrasonography for endometrium, and after, with biopsy of endometrium. All patients on long-term Tamoxifen therapy should be annually screened by endometrial biopsy for endometrial pathology.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources